DEVELOPMENT AND ASSESSMENT OF THE CILOSTAZOL SOLID DISPERSION EMPLOYING MELT AND SOLVENT EVAPORATION METHOD AND ITS COMPARISON

MAROOR NARAYANANKUTTY ANJANA; M. KUMAR; VENKATESWARLU B. S.; SANTHOSH M. MATHEWS; SAMPATH KUMAR K. P.

doi:10.22159/ijap.2023v15i6.48090

Authors

MAROOR NARAYANANKUTTY ANJANA Department of Pharmaceutics and Pharmaceutical Chemistry, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University) Salem-636008, Tamil Nadu, India https://orcid.org/0000-0002-0563-4331
M. KUMAR Department of Pharmaceutics and Pharmaceutical Chemistry, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University) Salem-636008, Tamil Nadu, India
VENKATESWARLU B. S. Department of Pharmaceutics and Pharmaceutical Chemistry, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University) Salem-636008, Tamil Nadu, India
SANTHOSH M. MATHEWS Department of Pharmaceutics, Pushpagiri College of Pharmacy, Thiruvalla-689101 India
SAMPATH KUMAR K. P. Department of Pharmaceutics, Coimbatore Medical College, Coimbatore-641018, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ijap.2023v15i6.48090

Keywords:

Cilostazol, FT-IR, Physical mixture, Solid Dispersion, Compatibility, In-vitro dissolution

Abstract

Objective: Development and assessment of the Cilostazol solid dispersion employing melt and solvent evaporation method and its comparison. BCS class II and IV drugs are low solubility and low permeability properties. Most of the active drugs are pharmacologically ineffective due to a lack of solubility and permeability. To overcome these problems Solid Dispersion (SD) is one of the best conventional methods. The objective of this study is to improve the dissolution rate of Cilostazol using economical and simple solid dispersion technique.

Methods: Physicochemical properties of Cilostazol was studied. Cilostazol and polymers (PEG 6000 and PVPK30) interactions were studied by FT-IR spectroscopy. SD was prepared using PVP K30 polymer by melt and solvent evaporation, and the polymer interactions of Cilostazol, Physical Mixture (PM), and SD were studied using FT-IR. Using a USP dissolution type 2 test apparatus (n=3) and settings of 50 rpm and 37 °C 0.5 °C, in vitro dissolution experiments for Cilostazol, PM and SD were conducted. Dissolution study and saturation solubility study was the main evaluating parameters.

Results: The FTIR study confirmed sharp peaks in the spectrum without merging, indicating that no drug interactions were present in the PM and SD formulations. Solubility and dissolution studies confirmed that drug release patterns of the pure drugs Cilostazol, PM (1:3), and SD (1:3) resulted in a markedly higher release rate. SD (1:3) released 97.2% of the drug after 60 min. PM (1:3) released 68.6% of the drug in 60 min, and the pure drug released 35.4% in 60 min. The formulation stability study confirmed that there was no significant loss of the drug under the storage conditions. The cilostazol SD was formulated using a conventional method. The solubility and drug release increased significantly (p<0.05) compared with Cilostazol and PM. FT-IR studies confirmed that there were no interactions between the drug and the polymer.

Conclusion: The present study concluded that cilostazol and PVP K30 Solid Dispersion (SD) was one of the choice used to enhance the solubility and drug release properties. However, in vivo studies are required before clinical application.

Downloads

Download data is not yet available.

References

Goto S. Cilostazol: a potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3-11. doi: 10.1016/j.atherosclerosissup.2005.09.002, PMID 16275169.

Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM. Cilostazol in acute ischemic stroke treatment (CAIST Trial): a randomized, double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65-71. doi: 10.1159/000327036, PMID 21613787.

Seo JH, Park JB, Choi WK, Park S, Sung YJ, Oh E. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate. Drug Des Devel Ther. 2015;9:3961-8. doi: 10.2147/DDDT.S87687. PMID 26251575.

Miyake M, Oka Y, Mukai T. Food effect on meal administration time of pharmacokinetic profile of cilostazol, a BCS class II drug. Xenobiotica. 2020 Mar 28;50(2):145-9. doi: 10.1080/00498254.2019.1602746, PMID 30938549.

Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet. 1999 Nov 24;37(2)Suppl 2:1-11. doi: 10.2165/00003088-199937002-00001, PMID 10702882.

Chatsiricharoenkul S, Nanchaipruek Y, Manopinives P, Atakulreka S, Niyomnaitham S. Bioequivalence study of 100-mg cilostazol tablets in healthy thai adult volunteers. Curr Ther Res Clin Exp. 2019 Jun 28;91:11-6. doi: 10.1016/j.curtheres.2019.06.004. PMID 31372190.

Doile MM, Fortunato KA, Schmücker IC, Schucko SK, Silva MA, Rodrigues PO. Physicochemical properties and dissolution studies of dexamethasone acetate-beta-cyclodextrin inclusion complexes produced by different methods. AAPS PharmSciTech. 2008 Feb 5;9(1):314-21. doi: 10.1208/s12249-008-9042-z, PMID 18446497.

Patel SG, Rajput SJ. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS PharmSciTech. 2009 May 21;10(2):660-9. doi: 10.1208/s12249-009-9249-7, PMID 19459053.

Işık M, Levorse D, Mobley DL, Rhodes T, Chodera JD. Octanol-water partition coefficient measurements for the SAMPL6 blind prediction challenge. J Comput Aided Mol Des. 2020 Dec 19;34(4):405-20. doi: 10.1007/s10822-019-00271-3, PMID 31858363.

Sammour OA, Hammad MA, Megrab NA, Zidan AS. Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion. AAPS PharmSciTech. 2006 Jun 16;7(2):E55. doi: 10.1208/pt070255, PMID 16796372.

Jun-Hyung H-KC. Enhancement of solubility and dissolution of cilostazol by solid dispersion technique. Arch Pharm Res. 2015 Jan 08;1(2).

Zhang S, Sun Y, Zhou L, Jiang Z, Yang X, Feng Y. Osmotic pump tablets with solid dispersions synergized by hydrophilic polymers and mesoporous silica improve in vitro/in vivo performance of cilostazol. Int J Pharm. 2020 Oct 15;588:119759. doi: 10.1016/j.ijpharm.2020.119759. PMID 32800938.

Jin G, Ngo HV, Cui JH, Wang J, Park C, Lee BJ. Role of surfactant micellization for enhanced dissolution of poorly water-soluble cilostazol using poloxamer 407-based solid dispersion via the anti-solvent method. Pharmaceutics. 2021 May 5;13(5):662. doi: 10.3390/pharmaceutics13050662, PMID 34063136, PMCID PMC8148127.